Shanghai MicroPort MedBot (Group) Co., Ltd.
上海微创医疗机器人(集团)股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2252)

POLL RESULTS OF THE 2024 ANNUAL GENERAL MEETING
APPOINTMENT OF DIRECTOR
CHANGE IN COMPOSITION OF NOMINATION COMMITTEE
AND
ESTABLISHMENT OF COMMERCIALISATION COMMITTEE

References are made to the notice (the "**Annual General Meeting Notice**") of the 2024 annual general meeting (the "**Annual General Meeting**") and the circular (the "**Circular**") of Shanghai MicroPort MedBot (Group) Co., Ltd. (the "**Company**") dated 27 May 2025. Capitalised terms used herein shall, unless otherwise defined, have the same meanings as those defined in the Circular.

The Board is pleased to announce that the Company convened and held the Annual General Meeting at 1601 Zhangdong Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, the PRC on Wednesday, 25 June 2025. All the proposed resolutions as set out in the Annual General Meeting Notice were duly passed by way of poll at the Annual General Meeting.

POLL RESULTS OF THE ANNUAL GENERAL MEETING

As at the date of the Annual General Meeting, the total number of Shares in issue was 1,031,330,331, which entitled the holders to attend the Annual General Meeting and vote for or against or abstain from voting on the resolutions proposed thereat. The Shareholders and proxies of Shareholders attending the Annual General Meeting held a total of 593,402,773 voting Shares, representing approximately 57.5% of the total number of issued Shares as at the date of the Annual General Meeting.

The poll results in respect of the resolutions proposed at the Annual General Meeting were as follows:

ORDINARY RESOLUTIONS		Number of Votes and Percentage of Total Number of Votes		
		FOR	**AGAINST**	**ABSTAIN**
1.	To consider and approve the 2024 Annual Report of the Company, which comprises the Group's audited consolidated financial statements, the 2024 report of the board (the "**Board**") of directors (the "**Directors**") of the Company and the auditors' report of the Company for the year ended 31 December 2024.	593,400,273 99.999579%	0 0.000000%	2,500 0.000421%
2.	To consider and approve the 2024 report of the supervisory committee of the Company.	593,400,273 99.999579%	0 0.000000%	2,500 0.000421%
3.	To consider and approve proposed 2024 annual profit distribution plan.	593,400,273 99.999579%	0 0.000000%	2,500 0.000421%
4.	To consider and approve the appointment of Mr. Liu Yu as an executive director of the Company, and to authorise the Board to fix his remuneration.	592,817,056 99.901295%	583,217 0.098284%	2,500 0.000421%
5.	To consider and approve the appointment of KPMG and KPMG Huazhen LLP as the overseas and domestic auditors of the Company and authorise the Board to fix their remuneration.	593,238,273 99.972279%	162,000 0.027300%	2,500 0.000421%
SPECIAL RESOLUTIONS		**Number of Votes and Percentage of Total Number of Votes**		
		FOR	**AGAINST**	**ABSTAIN**
6.	To grant a general mandate to the Directors to allot, issue and deal with additional Shares not exceeding 20% of the total number of issued Shares (including Domestic Shares and H Shares) of the Company; and to authorise the Directors to make such amendments as it deems appropriate to the provisions of the articles of association of the Company, so as to reflect the new capital structure upon additional allotment and issuance of shares pursuant to such mandate.	584,608,017 98.517911%	8,792,256 1.481668%	2,500 0.000421%

SPECIAL RESOLUTIONS		Number of Votes and Percentage of Total Number of Votes		
		FOR	AGAINST	ABSTAIN
7.	To grant a general mandate for the Directors and the persons authorised by the Directors to buy back Domestic Shares and/or H Shares of the Company not exceeding 10% of the total number of Domestic Shares and/or H Shares of the Company in issue at the time when this resolution is passed at the AGM.	593,400,273 99.999579%	0 0.000000%	2,500 0.000421%

In respect of each of the above ordinary resolutions numbered 1 to 5, as more than half of the voting rights represented by the Shareholders (including their proxies) attending the Annual General Meeting were cast in favour of each of these resolutions, all these resolutions were duly passed as ordinary resolutions at the Annual General Meeting. In respect of each of the above special resolutions numbered 6 to 7, as more than two-thirds of the voting rights represented by the Shareholders (including their proxies) attending the Annual General Meeting were cast in favour of each of these resolutions, all these resolutions were duly passed as special resolutions at the Annual General Meeting.

The Annual General Meeting was convened by the Board. Mr. Sun Hongbin, the non-executive Director and the chairman of the Board, was the chairman of the Annual General Meeting, and presided over the Annual General Meeting. All Directors attended the Annual General Meeting in person or by online conferencing.

Save as disclosed, as at the date of the Annual General Meeting, (i) there were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions proposed at the Annual General Meeting pursuant to Rule 13.40 of the Listing Rules; (ii) none of the Shareholders were required under the Listing Rules to abstain from voting at the Annual General Meeting; and (iii) none of the Shareholders had stated their intention in the Circular to vote against or to abstain from voting on the resolutions proposed at the Annual General Meeting.

Computershare Hong Kong Investor Services Limited, the Company's branch share registrar in Hong Kong, acted as the scrutineer for vote-taking at the Annual General Meeting.

APPOINTMENT OF DIRECTOR

The Board is pleased to announce that Mr. Liu Yu has been appointed as an executive Director with effect from the conclusion of the Annual General Meeting.

Please refer to the Circular for the biographical details of Mr. Liu and the information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules. Mr. Liu confirmed that there has been no change in his biographical details between the date of the Circular and the date of this announcement.

The Company has entered into a service contract with Mr. Liu. He will serve until the end of the second session of the Board.

The Board would like to extend its warmest welcome to Mr. Liu to join the Board.

CHANGE IN COMPOSITION OF NOMINATION COMMITTEE

The Board hereby announces that in light of the amendments to Corporate Governance Code and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, which will become effective on 1 July 2025, the change in composition of the nomination committee of the Company has been approved by the Board, with effect from 25 June 2025. The Nomination Committee will be adjusted to consist of Dr. He Chao and Ms. Fang Cong, being executive directors, and Mr. Chung Wai Man, Dr. Li Minghua and Mr. Yao Haisong, being independent non-executive directors, and Mr. Yao Haisong will continue to act as the chairperson.

ESTABLISHMENT OF COMMERCIALISATION COMMITTEE

The Board hereby announces that the Commercialisation Committee of the Board has been established by resolution of the Board. The establishment of the Commercialisation Committee aims to further optimise the planning and implementation of the Company's commercialisation system, and to fully leverage on the guidance of the Commercialisation Committee, so as to enhance the competitiveness edges of the Company's products in the market during commercialisation. The Commercialisation Committee consists of four members, including Dr. He Chao and Mr. Liu Yu, being executive directors, and Mr. Sun Hongbin and Mr. Chen Chen, being non-executive directors, and Mr. Liu Yu will act as the chairperson, with effect from 25 June 2025.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 25 June 2025

As at the date of this announcement, the executive Directors are Dr. He Chao, Ms. Fang Cong and Mr. Liu Yu, the non-executive Directors are Mr. Sun Hongbin and Mr. Chen Chen, and the independent non-executive Directors are Dr. Li Minghua, Mr. Yao Haisong and Mr. Chung Wai Man.